NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP
Bio-rad Laboratories, Inc. BIO
18 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 2.6B
Revenue, FY2025 · full 18-year series below
Revenue $B
Net income $B
FY2025 · Revenue 2.6 · Net income 0.8
Compound annual growth
−2.7%
+0.3%
+2.5%
+2.0%
−27.6%
+21.4%
+9.9%
−26.1%
+22.3%
+10.1%
+11.7%
+26.1%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +0.3% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
29 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 1.8% · Net 29.4%
ROE
FY2025 · ROE 10.8%
Each USD of equity produced 11 cents of profit this year.
The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 2.6 | 2.6 | 2.7 | 2.8 | 2.9 | 2.5 | 2.3 | 2.3 | 2.2 | 2.1 | 2.0 | 2.2 | 2.1 | 2.1 | 2.1 | 1.9 | 1.8 | 1.8 |
| Operating income $B | 0.0 | 0.3 | 0.3 | 0.5 | 0.5 | 0.4 | 0.2 | −0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 |
| EBITDA $B | 0.2 | 0.4 | 0.5 | 0.6 | 0.6 | 0.6 | 0.4 | 0.0 | 0.3 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 | · |
| Income tax $B | 0.2 | −0.5 | −0.2 | −1.1 | 1.2 | 1.1 | 0.5 | 0.1 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.8 | −1.8 | −0.6 | −3.6 | 4.3 | 3.8 | 1.8 | 0.4 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
| Free cash flow $B | 0.4 | 0.3 | 0.2 | 0.1 | 0.5 | 0.5 | 0.4 | 0.2 | −0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 |
| EPS, diluted $ | 27.85 | −65.36 | −21.82 | −121.79 | 140.83 | 126.47 | 58.27 | 12.10 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 10.8 | −24.1 | −6.9 | −31.1 | 36.1 | 48.8 | 36.0 | 10.5 | 4.4 | 1.0 | 4.7 | 4.1 | 3.7 | 8.8 | 10.9 | 13.3 | 11.5 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 88 reconciliationsAUDITED
Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityLaboratory Analytical Instruments
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008